Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy

Executive Summary

Everyone in the drug industry is eagerly waiting for any sign from FDA as to how it will handle biosimilar applications. So a recent meeting with a session devoted to FDA's current position on follow-on biologics was particularly tantalizing
Advertisement

Related Content

Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
FDA Creates Biosimilars Overseer In Drug Office; Internal Panel To Advise Application Reviewers
Biosimilars Pathway Has Blind Spots As FDA And Firms Begin Roadwork
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications

Topics

Advertisement
UsernamePublicRestriction

Register

PS052396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel